Sas version 9 3 or 9

Manufactured by SAS Institute

Sourced in Sweden, United States

SAS version 9.3 and 9.4 are statistical software applications that provide data management, analysis, and reporting capabilities. They offer a range of functionalities for data manipulation, statistical modeling, and visualization. The software is designed to help organizations gather, analyze, and interpret data to support decision-making processes.

Automatically generated - may contain errors

Lab products found in correlation

Stata v 13, by StataCorp (1 mentions)

Close spelling variants of this product

SAS 9.4 (20063 citations) SAS version 9.4 (18810 citations) SAS version (194 citations) Version 9.4 (20 citations) SAS version 9.3 or higher (13 citations) SAS 9.3 version (10 citations) SAS (SAS 9.3). (2 citations) SAS version 9.1.3 or higher (2 citations) SAS Version 9.3 or above (2 citations) SAS version 9.3 or later (2 citations)

4 protocols using sas version 9 3 or 9

Cilostazol Usage Patterns and Discontinuation

Check if the same lab product or an alternative is used in the 5 most similar protocols

The average annual prevalence of cilostazol use was calculated by using the age and sex distribution of the population in each database. The cumulative proportion of patients discontinuing cilostazol was calculated by using survival analysis. Rates of visits were calculated as the number of visits per 100 person‐years of continuous use of cilostazol, except in GePaRD, where the number of diagnoses per patient‐year was used. Crude incidence rate ratios and 95% confidence intervals were estimated to compare rates of visits between patients at high risk of cardiac complications and patients not at high risk.
At RTI Health Solutions (RTI‐HS; THIN data), SIDIAP, Sweden, and GePaRD, analyses were conducted by using sas version 9.3 or 9.4 (Cary, NC: SAS Institute Inc.). stata v13.0 (StataCorp, 2013) was used in the EpiChron cohort. stata v13.1 and R 3.1 (R Core Team, 2013) were also used in SIDIAP.
The protocol was approved by the EMA and posted in the EU PAS Register in March 2013 (EU PAS ID 3596).11

Castellsague J., Perez‐Gutthann S., Calingaert B., Bui C., Varas‐Lorenzo C., Arana A., Prados‐Torres A., Poblador‐Plou B., Gonzalez‐Rubio F., Giner‐Soriano M., Roso‐Llorach A., Linder M., Citarella A., Scholle O., Blenk T, & Garbe E. (2017). Characterization of new users of cilostazol in the UK, Spain, Sweden, and Germany. Pharmacoepidemiology and Drug Safety, 26(6), 615-624.

+ Open protocol

+ Expand

FGF23 Biomarker Changes in Chronic Kidney Disease

Check if the same lab product or an alternative is used in the 5 most similar protocols

The intended sample size was estimated to be 90 patients, which provided at least 80% power to detect the difference in mean changes of ESA dose per week from baseline to EOT (the primary endpoint) between two treatment groups with a type I error of 5% according to Wilcoxon rank sum test analysis; the results of two Japanese phase III trials with FC administration for 28 and 52 weeks were used as reference data. Baseline characteristics were summarized as descriptive statistics; differences between the FC and control groups were compared using either Student’s t-test (continuous variables) or Fisher’s exact test (categorical variables). Mean differences in biomarker levels between the FC and control groups were evaluated using analysis of covariance with baseline values as a covariate. Associations of the plasma levels or degree of change from baseline to EOT of α-klotho vs. those of i-FGF23 or c-FGF23 in each treatment group were evaluated by calculating Pearson’s correlation coefficient. Statistical analyses were performed using SAS version 9.3 or 9.4 (SAS Institute Inc., Cary, NC, USA).

Ito K., Yokoyama K., Nakayama M., Fukagawa M, & Hirakata H. (2021). Association of fibroblast growth factor 23 and α-klotho in hemodialysis patients during administration of ferric citrate hydrate: post hoc analysis of ASTRIO study. BMC Nephrology, 22, 374.

+ Open protocol

+ Expand

Statistical Analysis of Research Protocols

Check if the same lab product or an alternative is used in the 5 most similar protocols

CIs were calculated using traditional 95% two-sided intervals and all calculations were performed using SAS Version 9.3 or 9.4 (SAS Institute, Cary, NC).

Levi M., Vincent J.L., Tanaka K., Radford A.H., Kayanoki T., Fineberg D.A., Hoppensteadt D, & Fareed J. (2020). Effect of a Recombinant Human Soluble Thrombomodulin on Baseline Coagulation Biomarker Levels and Mortality Outcome in Patients With Sepsis-Associated Coagulopathy. Critical Care Medicine, 48(8), 1140-1147.

+ Open protocol

+ Expand

Phase 1 Safety and PK of AEF0117 in Healthy Adults

Check if the same lab product or an alternative is used in the 5 most similar protocols

The SAD and MAD phase 1 studies investigated AEF0117 safety and PK in healthy adult volunteers and were conducted at the Biotrial clinical facility. Biotrial also provided clinical support, including protocol development, study monitoring, data management, statistical analyses and clinical study report preparation.
Biotrial Bioanalytical Services, a subsidiary of Biotrial, carried out the analysis of AEF0117 in plasma and the PK analysis.
Clincase version 2.6 (Quadratek Data Solutions) was used for data management and SAS version 9.3 or 9.4 (SAS Institute) for the statistical analysis. Statistical analyses were performed following a SAP signed and filed before the database lock.

Haney M., Vallée M., Fabre S., Collins Reed S., Zanese M., Campistron G., Arout C.A., Foltin R.W., Cooper Z.D., Kearney-Ramos T., Metna M., Justinova Z., Schindler C., Hebert-Chatelain E., Bellocchio L., Cathala A., Bari A., Serrat R., Finlay D.B., Caraci F., Redon B., Martín-García E., Busquets-Garcia A., Matias I., Levin F.R., Felpin F.X., Simon N., Cota D., Spampinato U., Maldonado R., Shaham Y., Glass M., Thomsen L.L., Mengel H., Marsicano G., Monlezun S., Revest J.M, & Piazza P.V. (2023). Signaling-specific inhibition of the CB1 receptor for cannabis use disorder: phase 1 and phase 2a randomized trials. Nature Medicine, 29(6), 1487-1499.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!